08622.HK
Huakang Biomedical Holdings Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 0.18
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 38.5M | 28.3M | 25.4M | 24.6M | 25.3M |
| Cost of Revenue | 14.5M | 10.5M | 8.3M | 8.5M | 8.4M |
| Gross Profit | 24.0M | 17.8M | 17.1M | 16.1M | 16.9M |
| Operating Expenses | |||||
| R&D Expense | 5.1M | 3.9M | 2.8M | 2.6M | 2.5M |
| SG&A Expense | 28.1M | 22.4M | 19.3M | 18.5M | 18.8M |
| General & Admin Expense | 10.5M | 13.1M | 10.8M | 9.9M | 9.8M |
| Selling & Marketing Expense | 6.6M | 8.4M | 8.5M | 8.6M | 9.0M |
| Other Expenses | — | — | — | 2.4M | 767.0K |
| Total Operating Expenses | 33.2M | 26.3M | 22.1M | 23.5M | 22.0M |
| Cost and Expenses | 47.7M | 36.8M | 30.4M | 32.0M | 30.4M |
| Operating Income (EBIT) | (9.2M) | (7.8M) | (5.0M) | (7.4M) | (5.1M) |
| Non-Operating | |||||
| Interest Income | 357.2K | 315.6K | 512.0K | 404.0K | 409.0K |
| Interest Expense | 489.9K | 239.6K | 86.0K | 53.0K | 55.0K |
| Net Interest Income | (140.1K) | 76.0K | 426.0K | 351.0K | 354.0K |
| Other Non-Op Income/Expense | 3.0M | 2.8M | 853.0K | 1.6M | 2.1M |
| Non-Operating Income (excl Interest) | (510.0K) | — | (677.0K) | (754.0K) | (1.4M) |
| EBT (Pre-Tax Income) | (6.2M) | (5.0M) | (4.2M) | (5.8M) | (3.0M) |
| Income Tax Expense | — | — | — | — | 68.0K |
| Bottom Line | |||||
| Net Income | (6.1M) | (5.0M) | (4.2M) | (5.8M) | (3.1M) |
| Earnings from Cont. Ops | (6.2M) | (5.0M) | (4.2M) | (5.8M) | (3.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (6.1M) | (5.0M) | (4.2M) | (5.8M) | (3.1M) |
| Per Share | |||||
| Basic EPS | (HK$0.01) | (HK$0.01) | (HK$0.01) | (HK$0.01) | (HK$0.01) |
| Diluted EPS | (HK$0.01) | (HK$0.01) | (HK$0.01) | (HK$0.01) | (HK$0.01) |
| Revenue Per Share | HK$0.07 | HK$0.06 | HK$0.05 | HK$0.06 | HK$0.06 |
| Shares | |||||
| Basic Shares Outstanding | 515.5M | 501.4M | 482.4M | 416.0M | 404.6M |
| Diluted Shares Outstanding | 515.5M | 501.4M | 482.4M | 416.0M | 404.6M |
| Profitability Metrics | |||||
| EBITDA | (5.4M) | (6.2M) | (3.4M) | (2.5M) | 188.0K |
| D&A | 3.2M | 1.7M | 1.6M | 3.2M | 3.1M |
| EBIT | (8.7M) | (7.7M) | (5.0M) | (5.7M) | (3.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026